Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life

期刊论文
发表日期：

2024年6月13日

查看全文

David Balayssac,
Nicolas Kerckhove,
Marie Selvy,
Bruno Pereira,
Coralie Gonneau,
Caroline Pétorin,
Agnès Vimal-Baguet,
Sergey Melnikov,
Sharif Kullab,
Mohamed Hebbar,
Olivier Bouché,
Florian Slimano,
Vincent Bourgeois,
Valérie Lebrun-Ly,
Frédéric Thuillier,
Thibault Mazard,
David Tavan,
Kheir-Eddine Benmammar,
Brigitte Monange,
Mohamed Ramdani,
Denis Péré-Vergé,
Floriane Huet-Penz,
Ahmed Bedjaoui,
Florent Genty,
Cécile Leyronnas,
Denis Pezet,
Vincent Martin

摘要

Purpose

Sensory chemotherapy-induced peripheral neuropathy (CIPN) is well-recognized, but motor CIPN remains understudied. This secondary analysis focused on the long-term severity and impact of motor disorders, their relation to sensory CIPN, neuropathic pain, psychological distress, and health-related quality of life (HRQoL) after oxaliplatin-based chemotherapy in colorectal cancer (CRC) survivors.

Methods

Data from a multicenter, cross-sectional study were re-analyzed to explore motor CIPN among CRC survivors up to 5 years post-chemotherapy, with no longitudinal follow-up. Questionnaires assessed sensory and motor CIPN (QLQ-CIPN20), neuropathic pain (DN4), anxiety and depression (HADS), and HRQoL (QLQ-C30).

Results

Among 405 CRC survivors, 31.1% had sensory CIPN as previously described. When categorizing the 405 CRC survivors based on the years since their last oxaliplatin-based chemotherapy, the motor scores derived from the QLQ-CIPN20 showed no significant difference between years (p = 0.08). Motor CIPN scores correlated with female gender, higher oxaliplatin dose intensity, sensory CIPN, and neuropathic pain. Motor CIPN also linked to decreased HRQoL and increased psychological distress.

Conclusion

The study underscores the detrimental impact of motor disorders on CRC survivors post-oxaliplatin-based chemotherapy. Oncologists should prioritize assessing and managing motor manifestations alongside sensory symptoms to enhance post-cancer quality of life.

Trial registration: NCT02970526 (2016-11-22). https://classic.clinicaltrials.gov/ct2/show/NCT02970526?term=NCT02970526&draw=2&rank=1.